Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 120 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Severe Hemophilia A Clear all

Completed Phase 3 Interventional Results available

BAX 855 PK-guided Dosing

NCT02585960

View directory record Official record

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years

Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Source: ClinicalTrials.gov public record

Updated May 24, 2021 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 3 Interventional Results available

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

NCT01341912

View directory record Official record

Conditions: Severe Hemophilia A
Interventions: Human-cl rhFVIII; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years to 65 Years · Male only

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Source: ClinicalTrials.gov public record

Updated Mar 16, 2020 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 1 Interventional

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807

View directory record Official record

Conditions: Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Interventions: Emicizumab; Drug
Lead sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois; Other
Eligibility: 0 Years to 90 Years

Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 12
States / cities: Orange, California • Redwood City, California • Coral Gables, Florida + 9 more

Source: ClinicalTrials.gov public record

Updated Apr 2, 2026 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 2 Interventional Results available

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

NCT00623727

View directory record Official record

Conditions: Hemophilia A
Interventions: rFVIII-FS/pegylated liposomes (BAY79-4980), rFVIII-FS/WFI (BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 70 Years · Male only

Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Orange, California • Sacramento, California • San Francisco, California + 17 more

Source: ClinicalTrials.gov public record

Updated Jul 14, 2013 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 3 Interventional Results available

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

NCT01405742

View directory record Official record

Conditions: Severe Hemophilia A
Interventions: rF.VIII; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Male only

Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more

Source: ClinicalTrials.gov public record

Updated Oct 6, 2016 · Synced May 21, 2026, 10:13 PM EDT

Completed No phase listed Observational

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

NCT00195221

View directory record Official record

Conditions: Hemophilia B, Allergic Reactions
Interventions: Not listed
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: Not listed

Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more

Source: ClinicalTrials.gov public record

Updated Dec 4, 2007 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 3 Interventional

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127

View directory record Official record

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 74 Years · Male only

Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 13, 2026 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

NCT07226206

View directory record Official record

Conditions: Hemophilia A
Interventions: SPK-8011QQ; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Orange, California • Vallejo, California

Source: ClinicalTrials.gov public record

Updated Apr 26, 2026 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 2 Interventional Results available

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

NCT03061201

View directory record Official record

Conditions: Hemophilia A
Interventions: SB-525 (PF-07055480); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more

Source: ClinicalTrials.gov public record

Updated Sep 29, 2025 · Synced May 21, 2026, 10:13 PM EDT

Active, not recruiting Phase 3 Interventional

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319

View directory record Official record

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older · Male only

Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 8
States / cities: Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more

Source: ClinicalTrials.gov public record

Updated Feb 3, 2026 · Synced May 21, 2026, 10:13 PM EDT

Terminated No phase listed Observational

Goal Attainment and Physical Activity in People With Hemophilia A

NCT06530030

View directory record Official record

Conditions: Hemophilia A
Interventions: efanesoctocog alfa; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 50 Years

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Peoria, Illinois

Source: ClinicalTrials.gov public record

Updated Jan 19, 2026 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

NCT03587116

View directory record Official record

Conditions: Hemophilia B, Hemophilia A
Interventions: Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only

Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 13
States / cities: Palo Alto, California • San Francisco, California • Stanford, California + 7 more

Source: ClinicalTrials.gov public record

Updated Nov 5, 2025 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Prevention Trial

NCT04303559

View directory record Official record

Conditions: Hemophilia A Without Inhibitor
Interventions: Eloctate Injectable Product, Emicizumab Injection [Hemlibra]; Drug
Lead sponsor: Margaret Ragni; Other
Eligibility: 4 Months to 4 Years · Male only

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Little Rock, Arkansas • Pittsburgh, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Apr 10, 2023 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 4 Interventional Results available

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

NCT03103542

View directory record Official record

Conditions: Hemophilia A
Interventions: Recombinant coagulation factor (rFVIIIFc); Biological
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Male only

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Source: ClinicalTrials.gov public record

Updated Sep 18, 2024 · Synced May 21, 2026, 10:13 PM EDT

Completed No phase listed Observational

Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

NCT00936312

View directory record Official record

Conditions: Hemophilia A, Hemophilia B
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: Female only

Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Dec 9, 2012 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391

View directory record Official record

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, factor IX, factor VIII; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 5 Years and older

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more

Source: ClinicalTrials.gov public record

Updated Dec 28, 2023 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 1 Interventional

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

NCT00629837

View directory record Official record

Conditions: Hemophilia A
Interventions: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980), Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 60 Years · Male only

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Davis, California • Orange, California

Source: ClinicalTrials.gov public record

Updated Nov 17, 2014 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 4 Interventional

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT05935358

View directory record Official record

Conditions: Severe Hemophilia A
Interventions: Nuwiq; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years and older · Male only

Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Source: ClinicalTrials.gov public record

Updated May 11, 2026 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 4 Interventional

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673

View directory record Official record

Conditions: Hemophilia A
Interventions: Kogenate (BAY 14-2222); Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 60 Years · Male only

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Detroit, Michigan • Las Vegas, Nevada

Source: ClinicalTrials.gov public record

Updated Dec 17, 2014 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 1 Interventional

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820

View directory record Official record

Conditions: Hemophilia A
Interventions: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)); Biological
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years · Male only

Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Sep 6, 2018 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 3 Interventional

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

NCT01775618

View directory record Official record

Conditions: Hemophilia A
Interventions: BAY94-9027; Biological
Lead sponsor: Bayer; Industry
Eligibility: Up to 12 Years · Male only

Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 7
States / cities: Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more

Source: ClinicalTrials.gov public record

Updated Aug 20, 2020 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 1Phase 2 Interventional Results available

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

NCT04541628

View directory record Official record

Conditions: Hemophilia A
Interventions: SIG-001; Combination Product
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Sep 3, 2024 · Synced May 21, 2026, 10:13 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299

View directory record Official record

Conditions: Hemophilia A
Interventions: BAY2599023 (DTX201); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 3 Interventional

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

NCT03938792

View directory record Official record

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 74 Years · Male only

Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more

Source: ClinicalTrials.gov public record

Updated Jun 9, 2025 · Synced May 21, 2026, 10:13 PM EDT